KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Depreciation & Amortization (CF) (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Depreciation & Amortization (CF) for 13 consecutive years, with $18.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (CF) rose 50.0% year-over-year to $18.1 million, compared with a TTM value of $60.7 million through Dec 2025, up 39.46%, and an annual FY2025 reading of $60.7 million, up 39.46% over the prior year.
  • Depreciation & Amortization (CF) was $18.1 million for Q4 2025 at Travere Therapeutics, up from $15.8 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $18.1 million in Q4 2025 and bottomed at -$7.8 million in Q4 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $8.8 million, with a median of $9.7 million recorded in 2023.
  • The sharpest move saw Depreciation & Amortization (CF) crashed 217.91% in 2021, then skyrocketed 1547.04% in 2023.
  • Year by year, Depreciation & Amortization (CF) stood at -$7.8 million in 2021, then skyrocketed by 180.71% to $6.3 million in 2022, then skyrocketed by 50.32% to $9.5 million in 2023, then rose by 27.43% to $12.1 million in 2024, then skyrocketed by 50.0% to $18.1 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for TVTX at $18.1 million in Q4 2025, $15.8 million in Q3 2025, and $14.0 million in Q2 2025.